Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.

Cancer biology & therapy - 1 Nov 2009

Martin Aditi Pandya, Mitchell Clint, Rahmani Mohamed, Nephew Kenneth P, Grant Steven, Dent Paul

Abstract excerpt

Prior studies demonstrated that resistance to the ERBB1/2 inhibitor Lapatinib in HCT116 cells was mediated by increased MCL-1 expression. We examined whether inhibition of BCL-2 family function could restore Lapatinib toxicity in Lapatinib adapted tumor cells and enhance Lapatinib toxicity in naive cells. The BCL-2 family antagonist Obatoclax (GX15-070), that inhibits BCL-2/BCL-X(L)/MCL-1 function, enhanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2 Homologous Antagonist-Killer Protein
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HCT116 Cells

Share to Lapatinib

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Proto-Oncogene Proteins c-bcl-2

Share to Pyrroles

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 19823038
DOI: 10.4161/cbt.8.21.9895
PMCID: PMC3887451

Genes

ATG5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.PMID 19823038Read ↗

Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.Semantic proximity Read ↗

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisSemantic proximity Read ↗

FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET UpregulationSemantic proximity Read ↗

BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosisSemantic proximity Read ↗

EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.Semantic proximity Read ↗

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSemantic proximity Read ↗

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.Semantic proximity Read ↗

Mechanisms of lapatinib resistance in HER2-driven breast cancer.Semantic proximity Read ↗

Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin SignalingSemantic proximity Read ↗

Clinical evaluation of BCL-2/X<sub>L</sub> levels pre- and post- HER2-targeted therapySemantic proximity Read ↗

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.Semantic proximity Read ↗

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.